Australia has agreed to purchase another 50 million doses of two more Covid-19 vaccines, Prime Minister Scott Morrison said on Thursday.
It comes as Canberra aims to complete a mass inoculation programme within months.
Australia in September said it had agreed to spend A$1.7 billion (nearly £1 billion) to buy 85 million vaccine doses from AstraZeneca and CSL should their trials prove successful.
But seeking to maximise access to potential vaccines, Australia said on Thursday it had also agreed to purchase two other inoculations; 40 million doses from Novavax and 10 million from Pfizer and BioNTech.
“We aren’t putting all our eggs in one basket,” Mr Morrison said.
The deals with Novavax, Pfizer and BioNTech are worth about A$1.5 billion.
The Pfizer-BioNTech vaccine along with AstraZeneca’s and Novavax’s are among the leading candidates in the race to be the first to get regulatory approval in the United States and Europe.
Should trials prove successful, Australia expects to receive the first batches of the AstraZeneca vaccine in early 2021.
Australian Health Minister Greg Hunt said that should all go to plan, vaccinations would begin in March.
“The goal and the expectation is that Australians who sought vaccination will be vaccinated within 2021,” Mr Hunt said.